RFA-RM-22-024: Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on July 15, 2022.
From the official notice on Grants.gov, last changed April 15, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR03
- Clinical trialsNot allowed
- Funded byNCATS
- Median yearly award$155,771
- Typical project length1 year
- R03, Small Grant. A small, short project such as pilot work, a feasibility study, secondary data analysis or a new method, usually for up to two years. Other open R03 notices.
Projects funded under RFA-RM-22-024 were run by National Center for Advancing Translational Sciences (NCATS, 21 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-RM-22-024 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-RM-21-012 | April 1, 2021 | Closed July 15, 2021 | Closed |
Key dates
| Posted | April 15, 2022 |
|---|---|
| Deadline | July 15, 2022 |
| Archived by Grants.gov | August 20, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (72% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The goal of this funding opportunity announcement (FOA) for the Common Fund Program "Illuminating the Druggable Genome" (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDGs Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches. Awards will support the generation of additional data and tools around understudied protein(s) identified by the IDG Program to elucidate the function of these proteins in the context of human disease. Data collected and tools generated by these projects will enhance the overall goals of the IDG Program by demonstrating the quality and utility of IDG-generated data and reagents to the scientific community, increasing awareness of the IDG Program through use of IDG-generated resources, and/or extending the characterization of IDG-eligible proteins.
Funded under RFA-RM-22-024 so far
NIH funded 21 projects under RFA-RM-22-024 in fiscal 2023, at 21 institutions. The median yearly award was $155,771.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Biochemical Characterization of the CAMKV Pseudokinase | North Dakota State University | 2023 | $145,000 |
| Cyclin-dependent kinase (CDK)19-mediated vein graft intimal hyperplasia | University of Missouri-Columbia | 2023 | $156,500 |
| Mixed Lineage Kinase 2 (MLK2) and vascular homeostasis | Brigham and Women's Hospital | 2023 | $173,075 |
| Elucidating the Understudied Kinase PNCK as a Prospective Drug Target in Renal Cell Carcinoma | University of Miami School of Medicine | 2023 | $159,381 |
| The role of TTYH1 in glial cell autophagy | Rutgers the State Univ of NJ Newark | 2023 | $157,000 |
| Functional analysis of KCNK12 in dopaminergic neuroprotection | University of Alabama in Tuscaloosa | 2023 | $143,561 |
| Defining the MAST4 interactome in brain development and epilepsy | Seattle Children's Hospital | 2023 | $212,215 |
| Investigating the Effects of ADGRB3 Signaling on Incretin-Mediated Insulin Secretion from Pancreatic Beta-Cells | University of Alabama at Birmingham | 2023 | $164,125 |
Who has won Trans-NIH Research Support grants before
From fiscal 2021 to 2025, Trans-NIH Research Support (93.310) awarded $5.9 billion across 4,433 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Duke University | North Carolina | 66 | $219 million |
| The Leland Stanford Junior University | California | 104 | $176 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 82 | $154 million |
| The Johns Hopkins University | Maryland | 95 | $152 million |
| Yale Univ | Connecticut | 85 | $149 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-RM-22-024 still open?
No. It closed on July 15, 2022.
Who can apply for Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)?
Closed July 15, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-RM-22-024?
NIH RePORTER lists 21 projects funded under RFA-RM-22-024 in fiscal 2023, at 21 institutions. The most were at North Dakota State University, University of Missouri-Columbia, Brigham and Women's Hospital.
Who has won Trans-NIH Research Support grants before?
The largest recipients over five fiscal years were Duke University, The Leland Stanford Junior University, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 4,433 awards worth $5.9 billion in that time.
Similar open grants
- Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Pilot Projects to Enhance the Human Virome Program (R03 Clinical Trials Not Allowed)
- Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)
- Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)
- NICHD Small Research Grant Program (R03 Clinical Trial Required)